# Paroxetine

## Seroxat CR 12.5mg

##### 

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | OSER1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Indications        | ■Generalized anxiety disorder ■Major depressive disorder ■Obsessive-compulsive disorder ■Panic disorder ■Posttraumatic stress disorder ■Premenstrual dysphoric disorder ■Social phobia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Dosing             | Major depressive disorder: controlled-release， 25 mg/day orally in the morning; may increase dosage by 12.5-mg/day increments at intervals of at least 1 week to a maximum dose of 62.5 mg/day Panic disorder: controlled-release， 12.5 mg/day orally in the morning; may increase dosage by 12.5-mg/day increments at intervals of at least 1 week to a maximum dose of 75 mg/day Premenstrual dysphoric disorder: controlled-release， 12.5 mg/day orally in the morning; may increase to 25 mg/day at interval of at least 1 week; may be administered daily throughout the menstrual cycle or limited to daily administration during the luteal phase of the menstrual cycle Social phobia: controlled-release， 12.5 mg/day orally in the morning; may be increased by 12.5-mg/day increments at intervals of at least 1 week to a maximum dose of 37.5 mg/day                                                                       |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | ■coadministration with an MAOI， including linezolid or IV methylene blue， or use of paroxetine hydrochloride within 14 days of discontinuing an MAOI used to treat psychiatric disorders， or use of an MAOI used to treat psychiatric disorders within 14 days of discontinuing paroxetine hydrochloride; increased risk of serotonin syndrome ■concomitant use with pimozide ■concomitant use with thioridazine ■hypersensitivity to paroxetine or any component of the product                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | Common ■Cardiovascular: Palpitations (up to 3% )， Vasodilatation (2% to 4% ) ■Dermatologic: Diaphoresis (5% to 14% ) ■Gastrointestinal: Constipation (up to 16% )， Diarrhea (up to 18% )， Loss of appetite (up to 9% )， Nausea (up to 26% )， Xerostomia (9% to 18% ) ■Neurologic: Asthenia (up to 22% )， Dizziness (6% to 14% )， Headache (17% to 27% )， Insomnia (up to 24% )， Somnolence (up to 24%)， Tremor (4% to 11% ) ■Ophthalmic: Blurred vision (up to 5% ) ■Reproductive: Abnormal ejaculation (13% to 28% )， Impotence (2% to 9% )， Orgasm disorder (females; 2% to 9% )， Reduced libido (males: 6% to 15%; females: 0% to 9%) ■Respiratory: Yawning (4% ) Serious ■Dermatologic: Stevens-Johnson syndrome， Toxic epidermal necrolysis ■Hepatic: Acute hepatitis (rare) ■Neurologic: Seizure (0.1% ) ■Psychiatric: Depression， exacerbation， Suicidal thoughts (rare)， Suicide (rare) ■Other: Serotonin syndrome |
| Pregnancy          | Human (and animal) data suggest risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

